Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

5.770 +0.310 (+5.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
Psychedelic Stock Gainers And Losers From January 20, 2022
GAINERS: Small Pharma (OTC: 
Via Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC: 
Via Benzinga
MindMed Successfully Completes Phase 1 Trial Of 18-MC
This article was originally published on Microdose... 
Via Benzinga
Psilocybin and MDMA Get the Green Light for Medical Use in Canada
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – January 19, 2022 – After facing legal scrutiny for decades, psychedelics including MDMA and psilocybin received a stamp of... 
Via FinancialNewsMedia
Psychedelic Stock Gainers And Losers From January 18, 2022
GAINERS: Cybin (AMEX: 
Via Benzinga
MindMed Launches Study Using Monitoring System For Psychedelic Experiences
Psychedelics biotech company MindMed (NASDAQ:MNMD) has enr... 
Via Benzinga
Cannabis Movers & Shakers: MindMed, Halo Collective, Item 9, PSYC, Flora Growth
Stephen Hurst Steps Down From MindMed's Board Of Directors Psychedelic-focused biotech company Mind Medicine Inc 
Via Benzinga
Psyched: Canada's Access To Psychedelic Medicines, Psilocybin No Cognitive Side Effects, Psilocybin Bill Washington
Canada Opens New Legal Pathways For Access To Treatment With Psilocybin And MDMA In a groundbreaking decision, the Canadian gov... 
Via Benzinga
Pure-Play Marijuana- & Psychedelic Compounds-Based Drug Stocks Index Is Down By 66% From 2021 High
There are 16 remaining constituents of our Marijuana & Psychedelic Compounds-Based Drug Stocks Index is now DOWN -65.9% from its highs in 2021. Here are the details for each of its constituents. 
Via Talk Markets
A Recap of How Psychedelics Fared in 2021
Via Investor Brand Network
MindMed Completes Phase 1 Clinical Trial Of Non-Hallucinogenic Proprietary Derivative Of Ibogaine
On Tuesday, Mind Medicine Inc. (NASDAQ:MNMD) (NEO: MM... 
Via Benzinga
2021 Was The Year Psychedelics Conquered Capitalism...Or Is It The Other Way Around?
Witnessing an entirely new industry being created from scratch is a rare and historic event, one that brings with it tremendous opportunity for inv... 
Via Benzinga
Cannabis Movers & Shakers: MindMed & Trulieve Management Shake-Ups, Credex Corp & CapStone Bolster Leadership Teams
MindMed Announces Management Shake-Ups Mind Medicine Inc. (NASDAQ: 
Via Benzinga
Steep Decline In Cannabis & Psychedelic Compounds-Based Drug Stocks Continues: DOWN -16.6% MTD
All 12 constituents in the Marijuana & Psychedelic Compounds-Based Drug Stocks Index continue to decline. How do their performances compare month-to-date and YTD? 
Via Talk Markets
MindMed Shares Update On Phase 2b Trials of LSD For Treating Generalized Anxiety Disorder
MindMed (NASDAQ: MNMD) (NEO: MMED), a clinical-stage biotech company that is assembling a compelling drug development pipeline of innovative treatments based on psychedelic... 
Via Benzinga
The Year In Review For Psychedelic Drug Stocks: 2021
2021 was two different 
Via Talk Markets
MNMD Stock: The Latest Psychedelic Drug News MindMed Fans Should Watch
MindMed's LSD trials are facing a regulatory roadblock but MNMD stock isn't being forced down. Here's why investors should watch. 
Via InvestorPlace
Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD
A look at which index has done the best so far in December: the Marijuana Drug Stocks Index or the Psychedelic Compounds-Based Drug Stocks Index. 
Via Talk Markets
MindMed Advances Phase 2a LSD Microdose Trial For Adult ADHD
Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced Friday the initiation of Phase 2a proof-of-concept trial of LSD (... 
Via Benzinga
Mind Medicine to Study Effect of Time on LSD Microdosing
Mind Medicine (NASDAQ: MNMD), a psychedelic medicine biotech company, plans to conduct research on how the time of the day during which an individual consumes microdoses of a... 
Via Benzinga
Mind Medicine (NASDAQ: MNMD) (NEO: MMED) to Study Effect of Time on LSD Microdosing
Via Investor Brand Network
Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) to Conduct Study Investigating Effect of Time on LSD Microdosing
Via Investor Brand Network
Cannabis Movers & Shakers: HEXO, Agrify, MindMed, KetamineOne
Agrify Taps Barry Turkanis To Its Board Of Directors Vertically integrated cannabis company Agrify Corporation (NASDAQ... 
Via Benzinga
MindMed Names Robert Barrow As CEO & Director, Announces Management Shake-Ups
Psychedelic-focused biotech company Mind Medicine Inc. (NASDAQ: 
Via Benzinga
North American Psychedelic Drugs Market Expected To Reach A Value Of $3.184 Billion In 2026
Palm Beach, FL –December 14, 2021 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept... 
Via FinancialNewsMedia
Trip to Sustainability? This Company Is Developing Synthetic Psychedelics To Attempt to Fight Mental Illness
Photo by Raimond Klavins 
Via Benzinga
Fintech Focus For December 13, 2021
One Big Thing In Fintech: Understanding the fundamentals of a publicly-listed company can help with making more informed investment decisions. Still, many fail in conducting any... 
Via Benzinga
EXCLUSIVE: MindMed CEO Rob Barrow On Growth Aspirations, Development Pipeline
This past summer, Mind Medicine (MindMed) Inc (NASDAQ: MNMD), a medicine biotech in the psychedelics sector, announced the departure of co-founder and CEO J.R. Rahn. In learning... 
Via Benzinga
BioMedNewsBreaks – Mind Medicine (‘MindMed’) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) Engages with FDA for Development of the ‘MSMS’
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study
Psilera is a Florida-based biotechnology company focused on developing drugs to treat mental disorders using non-hallucinogenic derivatives from psychedelic compounds. The... 
Via Benzinga
Topics Derivatives
Exposures Derivatives
< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.